Temasek Invests in Series B in Glympse Bio
Posted on 07/16/2020
Cambridge, Mass.-based Glympse Bio, Inc. is a biotechnology company raised US$ 46.7 million in a Series B round. The capital raise will be used to support continued development of Glympse’s novel biosensor platform in fibrotic diseases such as Non-Alcoholic Steatohepatitis (NASH), oncology, and infectious diseases.
The financing round was led by Section 32 and includes new investors Singapore’s Temasek Holdings, DNS Capital, New Leaf Venture Partners, Waterman Ventures, and Catalio Capital Management, as well as existing investors, including LS Polaris Innovation Fund, ARCH Venture Partners, CRV, GreatPoint Ventures, Gilead Sciences, and others also participated. In connection with the financing, Steven Kafka, Ph.D., Managing Partner at Section 32, and George Zachary, General Partner at CRV, will join the Glympse Board of Directors. Cayce Denton, Director at Temasek, and Andrew Perlman, Managing Partner at GreatPoint Ventures, will join the Board as Observers.
